One the best take-aways of yesterdays CC was the now real

New Post Public Reply Private Reply Replies (2) Message Board
TechGuru
947
One the best take-aways of yesterdays CC was the now real and soon-to-happen possibility that we will be up-listing.

What was mentioned was to list in Amex Qualification standard 4

Quote:
Standard 4 is useful for new companies or established micro companies. There are no stockholders’ equity amounts or pre-tax income minimums to meet. The market value of your stock float must be at least $20 million and your stock price can’t be below $3 a share. You can meet the market capitalization requirement in one of two ways. Your company’s market capitalization can be $75 million or higher, or your company’s total assets can equal $75 million and your revenue be $75 million or higher.


So, what the CFO is trying to do is get the capitalization structure in place and apply to AMEX (NYSE-MKT.)

This will be huge for the SP. Why?? Because we don't have any institucional investors. The stock price is being maintained by little fish like you and me.

Currently we have 7 institucional investors (if we can call them institucional investors) with a sorry total of 10509565 shares (a bit more than 1% total).

The Big Boys normally can't invest in OTC companies:

Quote:
Most institutional investors simply can’t (by charter) or won’t invest in OTC stocks. And since this is the case, research analysts are reluctant to initiate coverage on stocks prior being listed on a major exchange, contributing to the lack of demand for the stock. But as soon as an uplisting occurs, institutional money flows in and drives up price and volume.


Or, to emphasize this:

Quote:
- Although there are no guarantees, uplisting usually provides greater liquidity in the issuers stock
- Liquidity is increased by widening the purchasing audience especially for large institutions previously unable to buy stocks unless listed on the NYSE or NASDAQ.
- The market perception of uplisting is very bullish and encourages investor confidence and can be a significant boost to a stock's price from increased buying pressure.


Some examples (somewhat old, but you get the point) from:

https://www.caseyresearch.com/daily-dispatch/...rtunities/

• RINO International (OTCPK:RINO) uplisted to the NASDAQ in July 2009 and initially saw its price jump 12% from $9.10 to over $10.19 the day the uplisting was announced. Since uplisting, the stock closed as high as $34.25 in November 2009 - more than 275% above its pre-NASDAQ price.
• Deer Consumer Products (OTCPK EER) saw its stock trade up over 50% in one week following the announcement it was approved for listing on the NASDAQ. And it's currently trading about 70% above its split adjusted pre-NASDAQ price.
• China Bio Energy (OTCPK:CBEH) was trading at $5 in July 2009 and then jumped 10% on the day of its NASDAQ approval. It now trades at $11.37 - more than 125% above its pre-NASDAQ price.
• L&L Energy (NASDAQ:LLEN) is up 75% since it was uplisted to the NASDAQ in February, while the NASDAQ overall is only up 15% over the same period.

So, once we up list it is likely that we will have a large uptick in the SP price and INSTITUCIONAL investors will come into play. These guys buy millions of shares at a time and, knowing that we do, the price will be a far cry to what it is today.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 5

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 6

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Portable Battery Charger Set to Transform EV Charging

Updated Category News Views 207

Introduction to the New Battery Charger for Electric Vehicles In a world where electric vehicles (EVs) are becoming more prevalent, the quest for convenience and reliability in charging options has led to the creation of an exciting new product. An inventive mind has developed a portable battery charger designed specifically for electric cars, addressing the significant...

Continue Reading
How to Calculate Rental Property Returns in Calgary

Updated Category Real Estate Views 549

The growth of the future value is not sufficient to invest in rental property, particularly in a market place such as Calgary where the economic cycles and population dynamics may affect the results. By computing the returns on the rental property, investors are able to know whether a property will be able to produce sustainable returns as they accumulate long te

Continue Reading
Understanding BioCardia's Upcoming Earnings Announcement

Updated Category News Views 196

BioCardia's Anticipated Earnings Report BioCardia (NASDAQ: BCDA) is gearing up for its next quarterly earnings announcement. Investors are keen to hear the results as they look to gain insights into the company's performance and future expectations. Expected Earnings Per Share Current estimates suggest that BioCardia will report an earnings per share (EPS) of...

Continue Reading
A New Look at Trump's First Month and Children's Concerns

Updated Category News Views 501

President Trump's Impact During His Initial Month As President Trump's new term unfolds, impactful events are shaping his administration's direction. The first month has been marked by significant developments, highlighted by the Senate's confirmation of Kash Patel as the Director of the FBI. This move is seen as a pivotal moment, emphasizing a commitment to addressing...

Continue Reading
Eramet Faces Revenue Decrease Amid Logistics Hurdles

Updated Category News Views 286

Eramet Revenue Decline in Q3 2025 Eramet has reported a decline in its adjusted turnover for the third quarter of 2025, which totaled €720 million. This marks a 10% decrease compared to the same quarter in 2024. The decrease primarily stems from significant external factors affecting sales and market conditions. Safety and CSR Achievements Despite facing a challenging...

Continue Reading